Rare Earth Breaking News - Defense Metals (TSX-V: $DEFN.V) (OTCQB: $DFMTF) Appoints Guy de Selliers as Chairman of the Board; @defensemetals

 

Vancouver, British Columbia - June 20, 2024 (Investorideas.com Newswire) Defense Metals Corp. ("Defense Metals" or the "Company") (TSX-V:DEFN / OTCQB:DFMTF/ FSE: 35D) is pleased to announce the appointment of Guy de Selliers as Chairman of the Board of Directors of the Company. 

 

Mr. de Selliers, a director of Defense Metals, is a highly experienced professional with an illustrious career and will bring over four decades of expertise and vision as the Chairman of the Boad of Defense Metals. 

 

Throughout his career, Mr. de Selliers has been a board member of numerous influential organizations including Solvay Group, Ageas Group, AG Insurance Belgium, Ivanhoe Mining, Advanced Metallurgical Group AMG, Norilsk Nickel, Wimm Bill Dann. He currently sits on the boards of I Pulse, a private high-tech company in France, The Cranemere Group Ltd., a privately held financial holding company in the UK, and Radix, a think-tank for the Radical Center (UK). He has been Chairman of the Board in a number of occasions most recently of AG Insurance, the largest Belgian Insurance company. He combines thus very strong corporate governance credential with extensive experience in mining, industry and finance. 

 

This news is paid advertisement/ news disseminated on behalf of/ issued on behalf of Defense Metals Corp.

 

Read this news, featuring DEFN in full at https://www.investorideas.com/news/2024/06201DEFN-Guy-de-Selliers.asp

 

About Defense Metals Corp. and its Wicheeda Rare Earth Element Project

Defense Metals Corp. is focused on the development of its 100% owned, 8,301-hectare (~20,534-acre) Wicheeda REE Project that is located on the traditional territory of the McLeod Lake Indian Band in British Columbia, Canada.

 

The Wicheeda REE Project, approximately 80 kilometres (~50 miles) northeast of the city of Prince George, is readily accessible by a paved highway and all-weather gravel roads and is close to infrastructure, including hydro power transmission lines and gas pipelines. The nearby Canadian National Railway and major highways allow easy access to the port facilities at Prince Rupert, the closest major North American port to Asia.

 

Defense Metals is a proud member of Discovery Group. For more information please visit:

www.discoverygroup.ca.

 

For further information, please visit www.defensemetals.com or contact:

 

Alex Heath

Vice President, Corporate Development  

Tel: 1 604-354-2491

Email: alex@defensemetals.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

 

Cautionary Statement Regarding “Forward-Looking” Information

 

This news release contains “forward–looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, statements relating to advancing the Wicheeda REE Project, the expectations and plans for the Wicheeda REE Project, the technical, financial and business prospects of the Company, its project, goals and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of rare earth elements, the anticipated costs and expenditures, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration and metallurgical results, risks related to the inherent uncertainty of exploration and development and cost estimates, the potential for unexpected costs and expenses and those other risks filed under the Company’s profile on SEDAR+ (www.sedarplus.ca). While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather and climate conditions, failure to maintain or obtain all necessary government permits, approvals and authorizations, failure to maintain or obtain community acceptance (including First Nations), risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of personnel, materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters), risks relating to inaccurate geological, metallurgical, engineering and pricing assumptions, decrease in the price of rare earth elements, the impact of viruses and diseases on the Company’s ability to operate, restriction on labour and international travel and supply chains, loss of key employees, consultants, officers or directors, increase in costs, delayed results, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward–looking statements or forward–looking information, except as required by law.

 

Defense Metals Corp. (TSX-V:DEFN /OTCQB:DFMTF) is a featured mining stock on Investorideas.com

 

More info on DEFN.V at Investorideas.com Visit: https://www.investorideas.com/CO/DEFN/

 

Get News Alerts on Defense Metals Corp DEFN

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure   this  DEFN news is a paid  featured annual mining stock  on investorideas.com – learn more about costs and services https://www.investorideas.com/News-Upload/  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp  Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com                                           

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Renewable Energy Stocks: investing ideas in renewable energy stocks

Like Renewable Energy Stocks? View our Renewable Energy Stocks Directory

Get News Alerts on Renewable Energy Stocks

 

Mining Sector Stocks- investing ideas in mining stocks

Like Mining Stocks? View our Mining Stocks Directory 

 Get News Alerts on Mining Stocks

 

Breaking Uranium Stock News - Pegasus (TSXV: $PEGA.V) (OTC PINK: $SLTFF) Shareholders Approve All Matters at the 2024 AGM; @pegasusresinc

Breaking Uranium Stock News - Pegasus (TSXV: $PEGA.V) (OTC PINK: $SLTFF) Shareholders Approve All Matters at the 2024 AGM; @pegasusresinc

 

Vancouver, Canada - June 19, 2024 (Investorideas.com Newswire) Pegasus Resources Inc. (TSX-V:PEGA) (OTCPK:SLTFF) (Frankfurt:0QS0) (the "Company" or "Pegasus") is pleased to announce that all resolutions were passed at the Annual General Meeting held on June 18, 2024.

 

The four nominees to be elected as directors listed in the Company's information circular dated May 14, 2024, were elected as directors of the Company for the ensuing year and the number of directors was fixed at four. Christian Timmins, Dave Bissoondatt, Noah Komavli and Derrick Strickland were all elected as directors of the Company by a majority of the votes cast by shareholders present or represented by proxy at the meeting.

 

Crowe MacKay LLP of Vancouver, British Columbia will remain as the auditor of the Company for the ensuing year until the next annual general meeting at a remuneration to be fixed by the directors. The Company's 10% rolling stock option plan also received the required shareholder approval.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Pegasus Resources Inc.

 

Read this news, featuring PEGA in full at https://www.investorideas.com/news/2024/06191PEGA-Shareholders-Approve-2024-AGM.asp

 

About Pegasus Resources Inc.

Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company with a focus on uranium, gold and base metal properties in North America. The Company is also actively pursuing the right opportunity in other resources to enhance shareholder value. For additional information please visit the Company at www.pegasusresourcesinc.com.

 

On Behalf of the Board of Directors:

 

Christian Timmins

President, CEO and Director
Pegasus Resources Inc.
700 - 838 West Hastings Street
Vancouver, BC V6C 0A6
PH: 1-403-597-3410

X: https://twitter.com/MrChris_Timmins
X: https://twitter.com/pegasusresinc
E: info@pegasusresourcesinc.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE: Pegasus Resources Inc.

 

Pegasus Resources Inc. (TSX-V:PEGA) (OTCPK:SLTFF) (Frankfurt:0QS0) is a featured mining stock on Investorideas.com

 

More info on PEGA at Investorideas.com Visit: https://www.investorideas.com/CO/PEGA/

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. Disclosure: Pegasus Resources Inc is a paid for mining client at InvestorIdeas.com. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

Recycling Metal Stocks – (NASDAQ: $GWAV) (NYSE: $LICY) (NASDAQ: $RDUS) (NASDAQ: $STLD) @GreenwaveGWAV @li_cycle @radiusrecycling

Recycling Metal Stocks – (NASDAQ: $GWAV) (NYSE: $LICY) (NASDAQ: $RDUS) (NASDAQ: $STLD) @GreenwaveGWAV @li_cycle @radiusrecycling

The Opportunities and the Players in Recycling Metal

 

June 18, 2024 – (Investorideas.com Newswire) Investorideas.com, a go-to platform for big investing ideas issues the first of a two-part series looking at the benefits, opportunities and the players in metals recycling, featuring Greenwave Technology Solutions, Inc. (Nasdaq:GWAV), an operator of metal recycling facilities in Virginia, North Carolina, and Ohio.

 

Research and Markets reports, “The rising demand for consumer electronics is significantly driving the growth of the metal recycling market. As the production and consumption of devices such as smartphones, laptops, tablets, and household appliances increase, so does the generation of electronic waste (e-waste). These devices contain valuable metals like copper, aluminum, gold, and silver, which can be recovered and recycled. Recycling metals from e-waste is crucial for conserving natural resources and reducing the environmental impact of mining and processing new metals.”

 

How big is the opportunity?  Research and Markets says the metal recycling market size is estimated to be USD 551.9 billion in 2024, and it is projected to reach USD 767.9 billion by 2029.

 

Tapping into the growth story, Greenwave Technology Solutions, Inc. (Nasdaq:GWAV), an operator of metal recycling facilities in Virginia, North Carolina and Ohio announced today that it has completed its recapitalization.

 

This article featuring Greenwave Technology Solutions, Inc. is paid for news dissemination.

 

Read this article, featuring GWAV in full at https://www.investorideas.com/news/2024/renewable-energy/06181Recycling-Metal-Stocks.asp

 

Greenwave’s Recent Highlights:

•         On track to generate record revenues exceeding $40 million driven by volume of steel and copper processed in 2024

•         Strengthened balance sheet by approximately $80.5 million since February

•         Attracts $45.3 million in new capital infusions since March

•         Current cash balance of over $26 million

•         Strongest cash position in Company history

•         Business plan is now fully funded

•         No current need to raise additional capital

•         Company is now in full compliance with all Nasdaq listing requirements

•         Intends to utilize additional cash flow from operations to aggressively grow and increase processing volume

•         Anticipates starting operations of its second shredder this summer

•         Plans to expand its wholly-owned technology platform, ScrapApp.com, nationwide and continue AI development

•         Plans to enhance margins of its downstream processing system with implementation of new copper extraction technology

•         Evaluating accretive acquisitions and strategic partnerships

•         Chairman and CEO exchanged approximately $17.2 million of debt into equity

 

Another recycler, Li-Cycle Holdings Corp. (NYSE: LICY), a leading global lithium-ion battery resource recovery company announced at the end of May that it had entered into a partnership with Daimler Truck North America for recycling lithium-ion batteries.

 

From the news: Li-Cycle and DTNA have a partnership to recycle lithium-ion batteries from DTNA electric vehicles that reach the end of their life cycle. Recycling lithium-ion batteries is part of DTNA’s plans to maximize battery lifespans and reduce material waste to tackle global sustainability challenges. DTNA’s strategy emphasizes repairing, remanufacturing, repurposing, and recycling lithium-ion battery materials.

 

"We are proud to partner with companies such as DTNA to support their sustainability and carbon reduction goals," said Ajay Kochhar, Li-Cycle President and CEO. "Our environmentally friendly and safe recycling technologies can recover critical materials to help create a domestic closed-loop battery supply chain, giving new life to these battery materials and helping power the world’s transition to clean energy."

 

Radius Recycling, Inc.  (NASDAQ: RDUS), is one of the largest manufacturers and exporters of recycled metal products in North America with operating facilities located in 25 states, Puerto Rico, and Western Canada. Radius has seven deep water export facilities located on both the East and West Coasts and in Hawaii and Puerto Rico.

 

As one of North America's largest metals recyclers, Radius facilities acquire, process, and recycle millions of long tons of ferrous metals and hundreds of millions of pounds of nonferrous metals every single year. These recycled metals represent critical feedstock in the global economy, supporting production of bridges, buildings, cars, public transit and passenger rail systems, and appliances, as well as more metal-intensive technologies, such as wind turbines, hydropower dams, advanced battery storage systems, upgraded electricity lines and electric vehicle charging stations, new broadband and reliable high-speed internet technology, and data centers.

 

In their May investor presentation they note the Drivers for Recycled Metals Demand:

 

Increased metal intensity, including copper and aluminum, of lower carbon-based technologies (e.g., EVs, renewable energy, development of“smart grids”)

 

Anticipated structural shortage of critical materials (e.g., copper, nickel and lithium)

 

Global EAF steelmaking production growth

 

Domestic investments related to Infrastructure

 

Investment and Jobs Act, Inflation Reduction Act, and Buy Clean provisions

 

Steel Dynamics, Inc. (NASDAQ:STLD), is one of the largest domestic steel producers and metals recyclers in North America, based on estimated annual steelmaking and metals recycling capability, with facilities located throughout the United States, and in Mexico.

 

In the first quarter earnings they reported, “Compared to the sequential fourth quarter, first quarter 2024 operating income from the company’s metals recycling operations increased to $23 million, based on increased demand supporting higher volume and metal spread expansion. Domestic steel production utilization increased from 74 percent in the sequential fourth quarter to 77 percent in the first quarter 2024. The team did an excellent job executing in a falling price environment since December 2023 before prices stabilized in April.”

 

Looking ahead to its potential growth, Greenwave Technology Solutions, Inc. (Nasdaq: GWAV),  says on its site, “ We have recently implemented several technologies to increase metal processing volumes and operating efficiencies, including a cloud-based ERP system to manage inventories and operations along with a website with live metal prices for each location.”

 

“We believe that these systems will create a solid foundation on which we can rapidly expand our facilities and scale our operations.”

 

Also as part of its strategy, GreenWave's wholly-owned subsidiary, Scrap App, Inc. ("Scrap App") previously announced it launched new AI-powered features to optimize pricing and sales. Greenwave anticipates Scrap App's planned national expansion, coupled with its AI strategy, will accelerate growth.

 

From the news: Greenwave is one of the first companies to utilize artificial intelligence in the $42.3 billion U.S. scrap metal industry (1). Scrap App has generated hundreds of thousands of dollars in revenue from end-of-life vehicles in the limited markets in which it's currently available -- Hampton Roads, VA, Richmond, VA, and Cleveland, OH.

 

American Recycler says,”There is indication that the metals recycling market is on the brink of substantial expansion, driven by the urgent need for an increased supply of critical minerals essential for the clean energy transition.”

 

Research more green stocks with Investorideas.com free stocks directory

https://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.

 

Disclaimer/Disclosure: This article featuring Greenwave Technology Solutions, Inc. (NASDAQ: GWAV) is a paid for content service on Investorideas. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses.  Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp  

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

Dawn Van Zant and Cali Van Zant

800 665 0411

 

Renewable Energy Stocks: investing ideas in renewable energy stocks

Like Renewable Energy Stocks? View our Renewable Energy Stocks Directory

Get News Alerts on Renewable Energy Stocks

 

Mining Sector Stocks - investing ideas in mining stocks

Like Mining Stocks? View our Mining Stocks Directory  Get News Alerts on Mining Stocks

 

 

 

 

 

 

Treatment of Blood Cancers – Stocks to watch (NYSE AMERICAN: $ATNM) (NASDAQ: $KURA) (NASDAQ: $SYRS) (NASDAQ: $SLS) @ActiniumPharma @kuraoncology @SyrosPharma @SellasLife

 

Treatment of Blood Cancers – Stocks to watch (NYSE AMERICAN: $ATNM) (NASDAQ: $KURA) (NASDAQ: $SYRS) (NASDAQ: $SLS) @ActiniumPharma @kuraoncology @SyrosPharma @SellasLife

 

Biopharma Companies Building out their Pipeline of Solutions

 

June 18, 2024 - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies.

 

Approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma. Approximately every 9 minutes, someone in the US dies from a blood cancer. This statistic represents approximately 157 people each day or more than six people every hour. This data from the Leukemia and Lymphoma Society demonstrates the growing and urgent demand for solutions.

 

Behind the scenes and the data, biopharma stocks are developing their unique approaches to treatment and building a pipeline of potential answers.    

 

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) is building out its pipeline and has recently announced progress on several products.

 

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies.

 

“Our Iomab-B and Actimab-A advanced product candidates fill the major unmet medical needs in relapsed or refractory AML in a complementary fashion directed at different parts of the patient journey,” they say on their website.

 

Paid news dissemination on behalf of Actinium

 

Read this article, featuring ATNM in full at https://www.investorideas.com/news/2024/biotech/06181Treatment-of-Blood-Cancers.asp

 

Actinium announced yesterday  that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium’s ARC Actimab-A in acute myeloid leukemia (AML) models was presented at the 2024 European Hematology Association (EHA) Congress held June 13 – 16, 2024, in Madrid, Spain. Actinium studied Actimab-A in combination with the leading menin inhibitors, revumenib (Syndax Pharmaceuticals, Inc.) and ziftomenib (Kura Oncology, Inc.), which are being developed for patients with KMT2A rearrangements and NMP1 mutations, which are present in approximately 10% and 30% of AML patients, respectively.

 

On June 14^th, Actinium announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain. The two presentations at EHA highlighted outcomes in patients with active relapsed or refractory acute myeloid leukemia (r/r AML) enrolled in the SIERRA trial who had a TP53 mutation and long-term efficacy results in this older patient population.

 

From the news: The Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active r/r AML and compared outcomes of patients receiving an Iomab-B led bone marrow transplant (BMT) to those of patients receiving physician's choice of care in the control arm. Across all patients in SIERRA study, only patients receiving an Iomab-B led BMT achieved the trial's primary endpoint of durable complete remission with these patients having 92% 1-year survival and 69% 2-year survival with statistically significant higher event free survival. The SIERRA trial enrolled high-risk patients including those with one or more of the following: a TP53 mutation, advanced age up to 77 years old, complex cytogenetics and prior therapy including venetoclax and other targeted agents.

 

Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes.

 

On June 11th, Actinium highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 – 11, 2024, in Toronto, Canada. Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Actimab-A has been studied as a single agent and in combination with chemotherapies and targeted therapies in Phase 1 and Phase 2 trials.

 

In mid-May, Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company’s menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The Company expects to report topline data from the trial in early 2025.

 

From the news: “We are thrilled to announce this critical milestone, which brings us one step closer to delivering ziftomenib as a potentially best-in-class treatment for patients with genetically defined acute leukemias,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Our confidence is supported by our recently announced Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), which recognizes ziftomenib’s potential as an innovative medicine for patients with R/R NPM1-mutant AML and is intended to expedite review as we prepare for submission of a New Drug Application. We are grateful for the KOMET-001 investigators, patients and their families, and we look forward to sharing topline data from this pivotal study early next year.”

 

Continued: Kura announced the first patients dosed in the Phase 2 portion of KOMET-001 in February 2023. The registration-directed study is designed to assess evidence of clinical activity, safety and tolerability of ziftomenib in patients with R/R NPM1-mutant AML, with a primary endpoint of complete response. The study has completed enrollment of the 85 patients necessary to support the primary endpoint analysis.

 

“The rapid enrollment of this study reflects the urgent need for more effective treatment options in AML as well as the potential for ziftomenib to address this need,” said Eunice Wang, M.D., Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center and principal investigator of the trial. “NPM1-mutant AML represents approximately 30% of new AML cases annually and is a disease of significant unmet need for which there is no approved targeted therapy. The favorable safety profile and encouraging clinical activity demonstrated by ziftomenib to date offer the potential to transform the standard of care for these AML patients.”

 

Syros Pharmaceuticals (NASDAQ:SYRS) is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.

 

Syros announced earlier this year that the United States Food and Drug Administration (USFDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test in adults who are over age 75 years or who have comorbidities that preclude the use of intensive induction chemotherapy. Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with venetoclax and azacitidine for the treatment of newly diagnosed AML patients with RARA gene overexpression.

 

"We are pleased to receive Fast Track designation for tamibarotene for the treatment of AML. This designation reflects the tremendous need for a safe and effective therapy, which can improve the clinical outcomes and prognosis among people diagnosed with AML, many of whom cannot tolerate intensive treatment," said David A. Roth, M.D., Chief Medical Officer of Syros Pharmaceuticals. "We are particularly encouraged to secure Fast Track designation following initial randomized data from a prespecified interim analysis of our ongoing SELECT-AML-1 clinical trial, in which treatment with our RARα agonist, tamibarotene, in combination with venetoclax and azacitidine resulted in a 100% CR/CRi rate compared with a 70% CR/CRi rate for the comparator of venetoclax and azacitidine. Additionally, tamibarotene in combination with venetoclax and azacitidine demonstrated no added toxicity relative to venetoclax and azacitidine alone. We look forward to sharing additional data from SELECT-AML-1 later this year, and to potentially accelerate the delivery of tamibarotene as a new frontline option for the approximately 30% of AML patients who are positive for RARA overexpression."

 

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications,  announced on June 10^th  the completion of enrollment as well as positive initial data from the ongoing Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).

 

From the news: “We are pleased to announce the completion of enrollment in the initial portion of our Phase 2a trial representing a significant milestone in the development of SLS009 in AML,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “There has been a high level of enthusiasm from the clinical sites, trial investigators, and patients, reflecting the significant unmet need in the AML patient population previously treated with venetoclax-based regimens. We are extremely grateful to everyone who has helped us achieve this important milestone ahead of schedule.”

 

Continued: Dr. Stergiou continued: “In addition, we are excited to share very promising initial data from this Phase 2a trial. Efficacy was demonstrated across all cohorts far exceeding the targeted ORR of 20% and median overall survival (mOS) of 3 months. The results also showed that SLS009 was well-tolerated across all doses. These data give us increased confidence in SLS009 as a potential new treatment for AML. We remain committed to advancing the treatment landscape for this underserved patient population and we look forward to continuing the trial, mainly the expansion cohorts, and reporting additional study updates and data in Q3 of this year.”

AML is one of the most common types of leukemia and its incidence is rising globally, including in the Asia-Pacific region, says DataBridgeInsights.

 

They also reported, “According to a survey by Bristol-Myers Squibb, approximately 1.85 million new cases of blood cancer will be diagnosed worldwide in 2040, with 918,872 cases of lymphoma, 656,345 cases of leukaemia, and 275,047 cases of myeloma. Furthermore, the survey predicted that by 2040, there will be around 1,100,000 fatalities worldwide owing to blood cancer.”

 

Biopharmaceutical stocks like Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) are on the hunt for solutions. Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it was studied in several Phase 1 and Phase 2 trials in almost 300 patients in multiple blood cancer indications, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM) and is currently being studied in several ongoing physician trials. Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the US Food and Drug Administration (USFDA) and the European Medicines Agency.

 

Read part one of the series on Investorideas.com

https://www.investorideas.com/news/2024/biotech/06171Biopharma-Stocks.asp

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This news article featuring ATNM is a paid for news release creation and dissemination on Investorideas.com.  Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories